Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.

Abstract

BACKGROUND:

No standard second-line combination chemotherapy has yet been established for patients with recurrent small cell lung cancer (RSCLC).

METHODS:

Patients with RSCLC were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan (CPT) at 50 mg/m2 on days 1 and 8 every 4 weeks for four cycles.

RESULTS:

The clinical outcomes of 12 patients (9 male and 3 female; age range 48-76 years, median 62 years) were retrospectively analyzed. Seven of the patients showed sensitive relapse. Two patients had a performance status of 2. Nine of the patients were able to receive 4 to 6 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia and thrombocytopenia occurred in 25.0%, 50.0% and 41.7% of patients, respectively. There were no grade 3 or 4 non-hematologic toxicities except for febrile neutropenia in 1 patient. There was no treatment-related death. Nine patients achieved PR, and the objective response rate was 75.0%. The median survival time was 11.1 months (range 4.8 to 31.3+ months) and the 1-year survival rate was 50.0%.

CONCLUSION:

NP and CPT in combination are effective and safe for patients with RSCLC.

• Authors: Miki Ohe, Fumihiro Oshita, Yoshiyuki Kenmotsu, Makiko Sugiura, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada
• Journal: Journal of experimental therapeutics & oncology (J Exp Ther Oncol) Vol. 10 Issue 1 Pg. 65-9 ( 2012) ISSN: 1359-4117 [Print] United States
• PMID: 22946345 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Organoplatinum Compounds
• Irinotecan
• nedaplatin
• Camptothecin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Camptothecin (administration & dosage, adverse effects, analogs & derivatives)
• Female
• Humans
• Irinotecan
• Male
• Middle Aged
• Organoplatinum Compounds (administration & dosage, adverse effects)
• Recurrence
• Retrospective Studies
• Small Cell Lung Carcinoma (drug therapy, pathology)
• Survival Rate